Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Adaptimmune Therapeutics PLC (ADAPY) Debt to Equity Ratio data is not available for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$5.92M |
|
$25.21M |
|
-- |
|
$5.92M |
|
$78.50M |
|
$-72.57M |
|
$-5.43M |
|
$-78.01M |
|
$-78.01M |
|
$-78.01M |
|
$-78.01M |
|
$25.21M |
|
$-78.01M |
|
$-72.57M |
|
$-55.38M |
|
262.83M |
|
272.41M |
|
$0.12 |
|
$0.12 |
|
| Balance Sheet Financials | |
$45.31M |
|
$7.80M |
|
$18.05M |
|
$63.36M |
|
$22.23M |
|
-- |
|
$9.15M |
|
$31.39M |
|
$31.97M |
|
$31.95M |
|
$31.97M |
|
265.05M |
|
| Cash Flow Statement Financials | |
$-121.91M |
|
$111.27M |
|
$-53.72M |
|
$91.14M |
|
$25.95M |
|
$-65.19M |
|
$-1.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.04 |
|
-- |
|
-- |
|
-- |
|
|
Debt to Equity Ratio |
-- |
100.00% |
|
-1225.05% |
|
-1225.05% |
|
-934.86% |
|
-1316.78% |
|
425.49% |
|
$-121.96M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
-- |
|
0.57 |
|
645.16 |
|
-244.01% |
|
-244.17% |
|
-123.12% |
|
-244.01% |
|
$0.12 |
|
$-0.45 |
|
$-0.45 |
|